| Fallacies from clinical trials | Hypertension. | Ruilope L M (Madrid, ES) |
| Fallacies from clinical trials | Dyslipidemia. | Barter P J (Sydney, AU) |
| Preventive cardiology in primary care - EUROASPIRE III | Design of EUROASPIRE III in primary care. | Wood D A (London, GB) |
| Preventive cardiology in primary care - EUROASPIRE III | Risk factor and therapeutic results. | Keil U (Muenster, DE) |
| Obese children - a growing target for life style intervention | Vascular dysfunction in obese children. | Erbs S (Leipzig, DE) |
| Obese children - a growing target for life style intervention | Nutrition - impact of interventional programmes. | Riccardi G (Naples, IT) |
| How to improve blood pressure control? | Scope of the problem. | Jones D W (Jackson, US) |
| How to improve blood pressure control? | Better antihypertensive drugs? | Kjeldsen S E (Oslo, NO) |
| How to improve blood pressure control? | The polypill? | Clement D L (Gent, BE) |
| Hot Line II | Coronary Artery Revascularisation in Diabetes. The CARDia trial. | Kapur A (London, GB) |
| Hot Line II | Coronary Artery Revascularisation in Diabetes. The CARDia trial - Discussant. | Fuster V (New York, US) |
| Rheumatic heart disease impact in developing world | Cardiovascular disease - a worldwide perspective. | Sheikh S A (Lahore, PK) |
| Rheumatic heart disease impact in developing world | What is the social and economic dimension of the problem? | Mayosi B M (Cape Town, ZA) |
| Rheumatic heart disease impact in developing world | Is prophylaxis reasonably achievable and is it a priority? | Halees Z Al (Riyadh, SA) |
| Targeting abdominal obesity and the metabolic syndrome to optimally manage global cardiovascular disease risk: exploring opportunities for prevention | Assessing the metabolic syndrome: does it matter in the evaluation of global cardiovascular disease risk? | Haffner S M (San Antonio, US) |
| Targeting abdominal obesity and the metabolic syndrome to optimally manage global cardiovascular disease risk: exploring opportunities for prevention | Abdominal obesity, metabolic syndrome and cardiovascular disease risk: the interventional cardiologist's perspective. | Steg P G (Paris Cedex 18, FR) |
| Targeting abdominal obesity and the metabolic syndrome to optimally manage global cardiovascular disease risk: exploring opportunities for prevention | Treating hypertension in the metabolic syndrome: is there a preferred drug? | Ruilope L M (Madrid, ES) |
| Clinical Trial Update II | Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation - results of the ADVANCE study. | Patel A (Sydney, AU) |
| Clinical Trial Update II | Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation - results of the ADVANCE study. - Discussant. | Le Heuzey J-Y (Paris, FR) |
| Clinical Trial Update II | Synergistic effect of perindopril and calcium channel blockers in prevention of cardiac events and death in coronary artery disease patients - analysis from the EUROPA study. | Bertrand M E (Lambersart, FR) |
| Clinical Trial Update II | Synergistic effect of perindopril and calcium channel blockers in prevention of cardiac events and death in coronary artery disease patients - analysis from the EUROPA study - Discussant. | Sever P S (London, GB) |
| Clinical Trial Update III | Blood Pressure Analyses from 25595 patients (from 25620 randomised) during the ONTARGET Trial: Reflections on Current Guidelines - Discussant. | Ruschitzka F T (Zurich, CH) |
| Clinical Trial Update III | The Euro CardioVascular Healthcare Index 2008. - Discussant. | Breithardt G (Munster, DE) |
| Clinical Trial Update III | EUROASPIRE III: Lifestyle, risk factor and therapeutic menagement in people at high risk of developing cardiovascular disease from 12 European regions. | Wood D A (London, GB) |
| Clinical Trial Update III | EUROASPIRE III: Lifestyle, risk factor and therapeutic menagement in people at high risk of developing cardiovascular disease from 12 European regions. - Discussant. | Ryden L (Stockholm, SE) |
| Highlight Session | Hypertension and risk factors. | Schunkert H (Lubeck, DE) |
| Highlight Session | Prevention. | Perk J (Oskarshamn, SE) |
| When and where is surgery worthwhile and cost-effective? | Rheumatic heart disease impact in developing world | Antunes MJ (Coimbra, PT) |